Technology | June 11, 2012

Mevion Medical Gains FDA Clearance for the Mevion S250 Proton Therapy System

Mevion S250 patented technology significantly reduces the cost of implementing and operating proton therapy centers.

June 11, 2012 — Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced that it has received U.S. Food and Drug Administration (FDA)  510(k) clearance for its Mevion S250 Proton Therapy System. The Mevion S250 is a first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment advantages and capabilities of complex, large, and costly proton therapy systems but with higher patient throughput, a significantly reduced footprint, improved reliability, and lower implementation and operational costs.  The Mevion S250 delivers precise and intense proton beams that physicians can use to treat tumors and lesions or any other condition where radiotherapy is indicated. 

The broad adoption of proton therapy has been greatly limited by the enormous cost, large footprint, and technical complexity of traditional proton therapy systems. Powered by a patented TriNiobium Core, the Mevion S250 proton therapy system redefines the economics, availability, and the future direction of proton therapy, by bringing the management and operation of proton therapy to levels similar to modern X-ray radiation therapy devices. 

This clearance enables users of the Mevion S250 to immediately treat patients upon completion of their system installation. The first installation of the Mevion S250 will soon be completed at the Kling Center for Proton Therapy at Barnes Jewish Hospital at Washington University in St. Louis, Mo.

Mevion will be delivering and installing more than a dozen Mevion S250 proton therapy systems worldwide within the next two years, making it one of the leading providers of proton therapy systems. Mevion S250 installations are also underway at Robert Wood Johnson University Hospital in New Jersey and Oklahoma University in Oklahoma. Additional sites in Florida and California will follow these installations.

Earlier this year, the Mevion S250 received CE certification, which gives Mevion the ability to market, sell, import, and install proton therapy systems in the European Union and other regions where the CE Marking is recognized.

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Baptist Hospital's Miami Cancer Institute Treats First Patient With Proteus Plus Proton Therapy
News | Proton Therapy | December 19, 2017
December 19, 2017 — IBA (Ion Beam Applications SA) announced that Miami Cancer Institute treated its first patients,
Mevion Achieves CE Mark for S250i Proton Therapy System
News | Proton Therapy | November 21, 2017
November 21, 2017 — Mevion Medical Systems announced the Mevion S250i...
RayStation Selected for New Tennessee Proton Therapy Center
News | Treatment Planning | November 20, 2017
November 20, 2017 — Provision Healthcare has selected RayStation for external beam planning at the new Provision Care
Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Sam Hancock, Ph.D.

Sam Hancock, Ph.D.

Sponsored Content | Case Study | Radiation Oncology | November 06, 2017
In establishing the new Southeast Cancer Center (Cape Girardeau, Mo.), clinic officials not only had the opportunity to...
Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH
Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the...
PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy
News | Proton Therapy | November 01, 2017
Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy...
Overlay Init